Capstone (CAPS) Competitors $1.79 -0.07 (-3.76%) As of 06/13/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock CAPS vs. NMTR, BIOR, TRVN, PTPI, HEPA, REVB, NCNA, VIRX, ATXI, and SYRSShould you be buying Capstone stock or one of its competitors? The main competitors of Capstone include 9 Meters Biopharma (NMTR), Biora Therapeutics (BIOR), Trevena (TRVN), Petros Pharmaceuticals (PTPI), Hepion Pharmaceuticals (HEPA), Revelation Biosciences (REVB), NuCana (NCNA), Viracta Therapeutics (VIRX), Avenue Therapeutics (ATXI), and Syros Pharmaceuticals (SYRS). These companies are all part of the "pharmaceutical products" industry. Capstone vs. Its Competitors 9 Meters Biopharma Biora Therapeutics Trevena Petros Pharmaceuticals Hepion Pharmaceuticals Revelation Biosciences NuCana Viracta Therapeutics Avenue Therapeutics Syros Pharmaceuticals Capstone (NASDAQ:CAPS) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap manufacturing companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation. Do institutionals and insiders have more ownership in CAPS or NMTR? 2.5% of Capstone shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 42.8% of Capstone shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is CAPS or NMTR more profitable? Capstone's return on equity of 0.00% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets CapstoneN/A N/A N/A 9 Meters Biopharma N/A -584.97%-159.45% Which has stronger earnings and valuation, CAPS or NMTR? Capstone has higher revenue and earnings than 9 Meters Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapstone$43.42M0.01N/AN/AN/A9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A Does the MarketBeat Community favor CAPS or NMTR? 9 Meters Biopharma received 37 more outperform votes than Capstone when rated by MarketBeat users. Likewise, 71.15% of users gave 9 Meters Biopharma an outperform vote while only 0.00% of users gave Capstone an outperform vote. CompanyUnderperformOutperformCapstoneOutperform VotesNo VotesUnderperform Votes1100.00% 9 Meters BiopharmaOutperform Votes3771.15% Underperform Votes1528.85% Which has more risk & volatility, CAPS or NMTR? Capstone has a beta of -0.83, meaning that its share price is 183% less volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Does the media favor CAPS or NMTR? In the previous week, Capstone had 7 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 7 mentions for Capstone and 0 mentions for 9 Meters Biopharma. Capstone's average media sentiment score of 0.34 beat 9 Meters Biopharma's score of 0.00 indicating that Capstone is being referred to more favorably in the media. Company Overall Sentiment Capstone Neutral 9 Meters Biopharma Neutral SummaryCapstone beats 9 Meters Biopharma on 6 of the 10 factors compared between the two stocks. Get Capstone News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPS vs. The Competition Export to ExcelMetricCapstonePharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$283K$6.88B$2.02B$8.50BDividend YieldN/A2.48%2.62%4.17%P/E RatioN/A8.4622.5519.65Price / Sales0.01261.9153.57152.07Price / CashN/A65.8551.7234.64Price / BookN/A6.522.104.59Net IncomeN/A$143.26M-$292.00M$248.23M7 Day Performance-3.76%-0.21%-0.45%-1.07%1 Month Performance7.83%10.62%3.38%2.59%1 Year PerformanceN/A3.63%19.39%13.50% Capstone Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPSCapstoneN/A$1.79-3.8%N/AN/A$283K$43.42M0.0038NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220BIORBiora Therapeutics1.7493 of 5 stars$0.14+0.7%$23.00+16,688.3%-98.0%$995K$892K-0.01120TRVNTrevena1.7406 of 5 stars$1.02+1.0%$5.00+390.2%-89.8%$978K$443K-0.0240Gap UpPTPIPetros Pharmaceuticals0.2837 of 5 stars$0.03-8.0%N/A-99.7%$966K$5.11M-0.0120Negative NewsShort Interest ↑Gap DownHEPAHepion Pharmaceuticals0.9946 of 5 stars$0.07+18.8%N/A-99.9%$767KN/A-0.0220News CoverageShort Interest ↓REVBRevelation Biosciences0.4323 of 5 stars$0.79-1.4%N/A-97.8%$765KN/A0.0010Short Interest ↑NCNANuCana3.6038 of 5 stars$0.11-24.4%$25.00+21,658.1%-96.2%$698KN/A-0.0130Positive NewsGap DownHigh Trading VolumeVIRXViracta Therapeutics1.9716 of 5 stars$0.02+4.8%$1.75+9,900.0%-97.4%$696KN/A-0.0220Gap DownATXIAvenue Therapeutics2.0135 of 5 stars$0.21-26.6%N/A-94.2%$663KN/A0.014Gap DownSYRSSyros Pharmaceuticals3.6991 of 5 stars$0.02-7.1%$3.33+14,847.7%-99.6%$598K$386K-0.01120Gap Up Related Companies and Tools Related Companies NMTR Alternatives BIOR Alternatives TRVN Alternatives PTPI Alternatives HEPA Alternatives REVB Alternatives NCNA Alternatives VIRX Alternatives ATXI Alternatives SYRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CAPS) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstone Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstone With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CAPS Stock Free CAPS Stock Alerts